Latest Breaking News On - Life sciences transformational health landscape - Page 1 : vimarsana.com

Search jobs The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 Adrenomyeloneuropathy is a rare genetic neuro-degenerative disease. Adrenomyeloneuropathy is the adult onset of adrenoleukodystrophy caused by the mutation in ABCD1 gene occurs usually in young boys. Adrenomyeloneuropathy disease affect the nerve cells in the spine and brain and the adrenal glands. Adrenomyeloneuropathy symptoms includes stiffness, weakness and pain in the legs. Adrenomyeloneuropathy is also known as ‘progressive spastic paraparesis. Damage to the nerves of the legs which causes unsteadiness and fall, also the bladder, bowel and sexual organs are affected by the adrenomyeloneuropathy. Rare diseases affect vast numbers of people, with current data representing 30 million sufferers in the EU alone and 30 million affected in the US. There is no cure to Adrenomyeloneuropathy. However some treatment might stop the progression of Adrenomyeloneu

New yorkUnited statesNovadip biosciencesAsia pacificStates europeCytori therapeuticsRare diseases information centerPersistence market researchLife sciences transformational health landscapeRequest methodologyNorth americaUnited states europeMiddle eastAdrenomyeloneuropathy treatmentAscend biopharmaceuticalsEureka therapeutics